Protection of biodiversity
There is increasing global recognition of the importance of healthy biodiversity. In October 2012, at the 11th conference of signatories to the Convention on Biological Diversity (CBD)  in Hyderabad, India, industrialized countries committed themselves to giving greater support to developing countries in implementing the international biodiversity goals.
New Group position on protecting biodiversity
Since the beginning of 2013, a new, Group-wide position on the protection of biodiversity has been in force at Bayer. This emerged from the existing Bayer CropScience subgroup position. It takes into account influences on biodiversity along the whole value-added chain and the sustainable use of raw materials. Particular attention is paid to product innovations that are of particular benefit to biodiversity. In this position, all subgroups commit themselves to the cbd. Bayer CropScience’s research and development activities include improving plant health, providing assistance in tackling invasive species and the support and implementation of measures to promote integrated crop management. Farmers and breeders can use Bayer CropScience products to improve their production efficiency, with the goal of reducing the area needed for agricultural use, which in turn leaves room for the preservation of valuable ecosystems with a large diversity of species.
By taking over the green agriculture company AgraQuest, Inc. in 2012, Bayer CropScience increased its portfolio to include biological crop protection, thereby enabling it to provide solutions for the growing market in ecological agriculture. Here you can find more information about the Bayer CropScience biodiversity projects, through which we support key elements of the European Union’s Biodiversity Action Plan (bap), and other specific examples of our promotion of biodiversity .
As a member of the German Association of Research-Based Pharmaceutical Companies (VFA) , Bayer HealthCare supports the association’s current position on the un Convention on Biological Diversity. In its search for new active ingredients, Bayer HealthCare concentrates on the chemical synthesis of substances using state-of-the-art technologies in medicinal, combinatorial and computational chemistry. Our work does not encompass research into natural substances. If they are used during research into new pharmaceuticals, they are first checked with respect to the cbd. At less than 5 percent, however, this is only a very minor aspect of our research activities.
By comparing our global site database with internationally relevant protected areas, last updated in May 2012, we were able to establish that our sites conform with the minimum distance allowed between a site and a protected area. A Group-wide directive also stipulates that new production sites must not be set up in areas that are protected by statutory requirements of the countries concerned with respect to natural characteristics, biodiversity or other factors. A minimum distance to such areas must also be observed. In order to limit the total area of land use at our production sites, we find new uses for unused land at Chempark locations or demolish disused buildings and renaturize the land. An example of this in the reporting period is the piece of land in Leverkusen that was previously the site of the Group headquarters.